However, the blockade of Siglec-G (activation of Src) while the patient is in the hyper-inflammatory phase or the activation of Siglec-G (blockade of Src) while in the hypo-inflammatory phase of sepsis may prove a useful treatment adjunct. The gene discussed is SRC; the disease is Sepsis.